News Sentiment

CRBU sentiment intelligence

Caribou Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.93 Week of 10 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+5.8% over one week, +20.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?

Market Reaction

Price moving ahead of tone

69/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction 5.8% Price confirming higher
Trend fit Trend inactive 20.7% over four weeks
Fair value -31.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 23
Neutral 29
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Stock Titan 8
TradingView 4
TradingKey 3
simplywall.st 3
marketscreener.com 2
Seeking Alpha 2
Moomoo 2

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 17
Analyst action 6
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-55 of 55
Stock Titan Direct company coverage

CRBU SEC Filings - Caribou Biosciences, Inc. 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for Caribou Biosciences, Inc. (CRBU) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, and 8-K material events. StockTitan tracks 32 SEC filings for CRBU, offering AI-generated summaries, impact scoring, and sentiment

Tone
Neutral 50/100
Event
Earnings
Published
22 May 2026 14:09
Source
Stock Titan
TradingView Direct company coverage

CRBU: Allogeneic CAR T programs show strong clinical progress and are advancing toward pivotal trials

Caribou Biosciences (CRBU) is making significant progress with its allogeneic CAR T cell programs. Vispa-cel has shown efficacy and safety comparable to autologous CAR T, positioning it for a pivotal Phase III trial. Additionally, CB-011 has demonstrated strong early results in m

Tone
Positive 92/100
Event
Earnings
Published
19 May 2026 20:09
Source
TradingView
AD HOC NEWS Direct company coverage

Caribou Biosciences stock (US1420381089): Q1 update and CRISPR pipeline stay in focus

Caribou Biosciences (CRBU) recently reported its Q1 2026 earnings, posting a smaller-than-expected loss per share. As a clinical-stage biotechnology company, its valuation is primarily driven by progress in its CRISPR-based genomic editing pipeline, rather than commercial sales.

Tone
Neutral 50/100
Event
Earnings
Published
19 May 2026 20:09
Source
AD HOC NEWS
Traders Union Direct company coverage

Caribou Biosciences brings CMO and CFO to BioConnect Investor Conference fireside chat

Caribou Biosciences will participate in the HCWCO 4th Annual BioConnect Investor Conference with a fireside chat featuring Chief Medical Officer Tina Albertson and Chief Financial Officer Sri Ryali. This event offers investors and industry stakeholders a chance to directly engage

Tone
Positive 66/100
Event
Market update
Published
18 May 2026 15:39
Source
Traders Union
AD HOC NEWS Direct company coverage

Caribou Biosciences stock (US1420381089): fresh data from latest CAR?T update keeps investors watchi

Caribou Biosciences released new clinical data for its lead off-the-shelf CAR-T candidate for lymphoma, drawing investor attention to the gene-editing company. The data, disclosed in early May 2026, highlighted response durability and safety, influencing expectations for Caribou'

Tone
Positive 70/100
Event
Market update
Published
16 May 2026 18:40
Source
AD HOC NEWS